ClinicalTrials.gg
CompletedNCT02039726Updated Feb 24, 2021Results posted

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

A Phase 3 interventional study of Quizartinib and Salvage Chemotherapy in AML, sponsored by Daiichi Sankyo. Completed at 131 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
6th of 28
367 · median 69
Started
2014
the only one that year
Phase 3
5 of 28
1 open now
Registered
7th of 28
by date
Lead sponsor
10 of 28
Daiichi Sankyo

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 7th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.

03

Conditions studied

  • AML

Keywords

  • Acute Myeloid Leukemia
  • AML
  • FMS-like tyrosine kinase 3
  • FLT3-ITD
  • Quizartinib
  • Leukemia
  • Tablets
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) with privacy language in accordance with national regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] authorization for United States [US] sites) prior to any study related procedures, including withdrawal of prohibited medications if applicable.
  2. Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of Informed consent.
  3. Morphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS), as defined by World Health Organization (WHO) criteria, as determined by pathology review at the study site.
  4. In first relapse (with duration of remission of 6 months or less) or after prior therapy, with or without . Induction therapy must have included at least 1 cycle of an anthracycline/mitoxantrone-containing induction block at a standard dose.
  5. Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood (allelic ratio as determined by a central laboratory with a cutoff of ≥3% FLT3-ITD/total FLT3). If a specimen has been sent for FLT3-ITD testing at the central laboratory but the subject requires treatment for AML before the central FLT3-ITD test result is available, a local test result may be acceptable for randomization after consultation with the Medical Monitor.
  6. Eligibility for pre-selected salvage chemotherapy, according to the Investigator's assessment.
  7. (ECOG) performance score 0-2.
  8. Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea or other treatment to control leukocytosis) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non cytotoxic agents.
  9. Serum creatinine ≤1.5× (ULN), or >25 mL/min, as calculated with the formula.
  10. Serum potassium, magnesium, and calcium (serum calcium corrected for hypoalbuminemia) within institutional normal limits. Subjects with electrolytes outside the normal range will be eligible if these values are corrected upon retesting following any necessary supplementation.
  11. Total serum ≤1.5×ULN.
  12. Serum (AST) and/or alanine transaminase (ALT) ≤2.5×ULN.

Exclusion criteria

Exclusion Criteria:

  1. Acute Promyelocytic Leukemia (AML subtype M3).
  2. AML secondary to prior chemotherapy for other neoplasms, except AML secondary to prior Myelodysplastic Syndrome (MDS).
  3. History of another , unless the candidate has been disease-free for at least 5 years.
  4. Persistent, > Grade 1 non-hematologic toxicity from prior AML therapy.
  5. Clinically significant (GVHD) or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or > Grade 1 persistent or clinically significant non hematologic toxicity related to .
  6. History of or current, central nervous system involvement with AML.
  7. Clinically significant coagulation abnormality, such as disseminated intravascular coagulation.
  8. Prior treatment with quizartinib or participated in a prior quizartinib study.
  9. Prior treatment with a FLT3 targeted therapy including sorafenib or FLT3 inhibitors (not including the multi-kinase inhibitor, midostaurin).
  10. Major surgery within 4 weeks prior to screening.
  11. Radiation therapy within 4 weeks prior to screening.
  12. Uncontrolled or significant cardiovascular disease
  13. Active infection not well controlled by antibacterial or antiviral therapy.
  14. Known infection with , or active or C, or other active clinically relevant liver disease.
  15. Unwillingness to receive infusion of blood products according to the protocol.
  16. In a man whose sexual partner is a woman of , unwillingness or inability of the man or woman to use a highly effective method for the entire study treatment period for at least 3 months after study completion. Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and 105 days after the final study drug administration.
  17. In a heterosexually active woman of childbearing potential, unwillingness or inability to use a highly effective contraceptive method for the entire study treatment period and for at least 3 months after study treatment completion. Additionally, for women randomized to chemotherapy, unwillingness to adhere to the restrictions in the respective locally established guidelines and local approved label (prescribing information, Summary of Product Characteristics, or US product insert) from the manufacturer and the Patient Information Leaflet (package insert) as instructed by the Investigator.
  18. Pregnancy.
  19. Female Subjects must agree to not breastfeed from the time of Screening and throughout the study period, and for 25 days after the final study drug administration.
  20. Medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the candidate's safety as a study subject, or that could interfere with study objectives.
  21. For subjects in the United Kingdom only: Refusal of permission to allow the subject's General Practitioner to be notified of their participation in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    Quizartinib

    Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.

    Drug: Quizartinib

  • Active comparator
    Salvage chemotherapy

    Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.

    Drug: Salvage Chemotherapy

Interventions

  • 20 or 30 mg quizartinib tablets administered orally once daily

    Also known as: AC220

  • DrugSalvage Chemotherapy

    Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles

    Also known as: Standard of Care

06

What researchers measure

Primary outcomes

  1. Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy

    Overall Survival is defined as the time (in weeks) from the date of randomization to the date of death due to any cause. Median and quartiles are calculated using the Kaplan-Meier method.

    Time frame: At approximately 3 years 9 months

Secondary outcomes

  1. Event-free Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy

    Event-free survival is defined as the time (in weeks) from randomization until documented refractory disease, relapse after complete composite remission (CRc), or death from any cause, whichever is observed first.

    Time frame: At approximately 3 years 9 months

07

Results

Posted Jan 27, 2020

Participant flow

A total of 367 participants who met the inclusion and none of the exclusion criteria were randomized (intent-to-treat population); 335 received study drug (safety analysis set).

Participant flow — Overall Study
MilestoneQuizartinibSalvage Chemotherapy
Started245122
Ongoing (as of data cutoff)4516
Did not receive treatment428
Completed200106
Not completed4516

Outcome measures

PrimaryOverall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy

Overall Survival is defined as the time (in weeks) from the date of randomization to the date of death due to any cause. Median and quartiles are calculated using the Kaplan-Meier method.

Time frame:
At approximately 3 years 9 months
Reported as:
Median · weeks
Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy
weeksQuizartinibSalvage Chemotherapy
Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy27.0 (15.4 to 62.6)20.4 (8.3 to 39.6)
Statistical analysis
  • Quizartinib vs Salvage Chemotherapy · P-value for HR=1 (1-sided) · p = 0.0185 · Hazard ratio (hr): 0.758 · 95% CI 0.584 to 0.983
SecondaryEvent-free Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy

Event-free survival is defined as the time (in weeks) from randomization until documented refractory disease, relapse after complete composite remission (CRc), or death from any cause, whichever is observed first.

Time frame:
At approximately 3 years 9 months
Reported as:
Median · weeks
Event-free Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy
weeksQuizartinibSalvage Chemotherapy
Event-free Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy6.0 (0.1 to 19.7)3.7 (0.1 to 17.0)
Statistical analysis
  • Quizartinib vs Salvage Chemotherapy · P value for HR=1 (1-sided) · p = 0.2034 · Hazard ratio (hr): 0.898 · 95% CI 0.697 to 1.157

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from the first dose of study drug to 30 days after the last dose (or longer if assessed as treatment related). All safety events are reported for participants in the Safety Analysis Set who received at least 1 dose of study drug or salvage chemotherapy.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quizartinib80/241 (33.2%)168/241 (69.7%)238/241 (98.8%)
Salvage Chemotherapy16/94 (17%)37/94 (39.4%)91/94 (96.8%)
Most frequent serious events
Showing 10 of 164
Most frequent serious events
EventQuizartinibSalvage Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders50/2419/94
PneumoniaInfections and infestations22/2413/94
SepsisInfections and infestations16/2414/94
PyrexiaGeneral disorders8/2412/94
Escherichia sepsisInfections and infestations2/2413/94
Neutropenic sepsisInfections and infestations7/2412/94
AnemiaBlood and lymphatic system disorders6/2410/94
CellulitisInfections and infestations6/2410/94
Urinary tract infectionInfections and infestations6/2410/94
Hemorrhage intracranialNervous system disorders5/2412/94
Most frequent other events
Showing 10 of 78
Most frequent other events
EventQuizartinibSalvage Chemotherapy
NauseaGastrointestinal disorders114/24139/94
PyrexiaGeneral disorders88/24142/94
DysuriaRenal and urinary disorders15/24139/94
DiarrheaGastrointestinal disorders68/24134/94
AnemiaBlood and lymphatic system disorders86/24129/94
VomitingGastrointestinal disorders80/24120/94
HypokalemiaMetabolism and nutrition disorders76/24125/94
FatigueGeneral disorders67/24118/94
Electrocardiogram QT prolongedInvestigations63/2412/94
ThrombocytopeniaBlood and lymphatic system disorders62/24120/94

Baseline characteristics

Participants received standard of care salvage chemotherapy (administered subcutaneously \[LoDac\] or intravenously \[MEC and FLAG-IDA\]).

Age, Categorical
Age, Categorical(Participants)QuizartinibSalvage ChemotherapyTotal
<=18 years000
Between 18 and 65 years18089269
>=65 years653398
Age, Continuous
Age, Continuous(years)QuizartinibSalvage ChemotherapyTotal
Median55.0 (19 to 81)57.5 (18 to 78)56.0 (18 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)QuizartinibSalvage ChemotherapyTotal
Female13258190
Male11364177
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QuizartinibSalvage ChemotherapyTotal
American Indian or Alaska Native101
Asian241640
Native Hawaiian or Other Pacific Islander000
Black or African American9312
White18493277
More than one race000
Unknown or Not Reported271037
Region of Enrollment
Region of Enrollment(participants)QuizartinibSalvage ChemotherapyTotal
Singapore022
Hong Kong538
Hungary101
United States8236118
Czechia202
United Kingdom211435
Spain15621
Canada18523
Netherlands213
South Korea11718
Belgium101
Taiwan213
Poland202
Italy341953
Australia336
France20727
Serbia101
Germany251843
08

Study locations

131 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of Southern California, Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • UC Davis Cancer Center
    Sacramento, California 95817, United States
  • Stanford University Medical Center Stanford Comprehensive Cancer Center
    Stanford, California 94305, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60607, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Franciscan Alliance
    Indianapolis, Indiana 46237, United States
  • University of Kansas Medical Center Research Institute Inc
    Westwood, Kansas 66205, United States
  • LSU Health Sciences Center Feist Weiller Cancer Center
    Shreveport, Louisiana 71103, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • NY Medical College
    Valhalla, New York 10595, United States
  • UNC Linebreger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
  • Duke Cancer Institute at Duke University Health System
    Durham, North Carolina 27710, United States
  • Wake Forest University Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Oregon Health and Science University Knight Cancer Institute
    Portland, Oregon 97239, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Center, The University of Texas
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • The Canbera Hospital
    Garran, New South Wales 2605, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • The Princess Alexandra Hospital
    Brisbane, Queensland, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Queen Elizabeth Hospital
    Woodville, South Australia 5011, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • ZNA Stuivenberg
    Antwerpen, BE 2060, Belgium
  • UCL St Luc
    Brussels, BE 1200, Belgium
  • Leuven UZ Gasthuisberg
    Leuven, BE 3000, Belgium
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Princess Margaret Cancer Centre Princess Margaret Hospital
    Toronto, Ontario M5G2M9, Canada
  • Klinička Bolinca Merkur
    Zagreb, 10000, Croatia
  • Kliničko Bolnički Centar Zagreb
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno
    Brno, 62500, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 77900, Czechia
  • CHU de Caen
    Caen, 14000, France
  • Centre Hospitalier Universitaire Grenoble Hopital Michalon
    Grenoble, 38043, France
  • Centre Hospitalier de Versailles
    Le Chesnay, 78157, France
  • Hopital de la Conception
    Marseille, 13385, France
  • Centre Hospitalier Universitaire Nantes
    Nantes, 44035, France
  • Hôpital Saint Louis
    Paris, 75010, France
  • Hopital Saint-Antoine
    Paris, 75571, France
  • Hopital Haut Leveque Centre Francois Magendie
    Pessac, 33604, France
  • Centre Henri-Becquerel
    Rouen, 76038, France
  • Centre Hospitalier Universitaire Purpan
    Toulouse, 31059, France
  • Charité Universitätsmedizin Berlin
    Berlin, 12200, Germany
  • Charité Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Klinikum Braunschweig
    Braunschweig, 38114, Germany
  • Universitatsklinikum Dresden
    Dresden, 01307, Germany
  • Klinikum der Johann Wolfgang-Goethe-Universität
    Frankfurt, 60590, Germany
  • Universitätsklinikum Halle
    Halle, 06120, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Uniklinik Heidelberg Medizinische Klinik und Poliklinik V
    Heidelberg, 69120, Germany
  • Universitätsklinikum Jena
    Jena, 07743, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • University Mainz
    Mainz, 55131, Germany
  • Universitätsklinikum Giessen und Marburg GmbH
    Marburg, 35043, Germany
  • LMU München Klinikum Großhadern
    Munchen, 81377, Germany
  • Medizinische Klinik A Hämatologie Hämostaseologie Internistische Onkologie und Pneumologie
    Münster, 48149, Germany
  • The Chinese University of Hong Kong, Prince of Wales Hospital
    Hong Kong, Hong Kong
  • The University of Hong Kong, Queen Mary Hospital
    Hong Kong, Hong Kong
  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Szent Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrad 6725, Hungary
  • Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Intezet
    Debrecen, Hajdu Bihar 4032, Hungary
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar I. Belgyogyaszati Klinika
    Budapest, Pest 1083, Hungary
  • AOU Policlinico Consorziale di Bari
    Bari, 70124, Italy
  • Università di Bologna
    Bologna, 40138, Italy
  • Unità Operativa di Ematologia e Unità Operativa CTMO
    Cagliari, Italy
  • Arcispedale S Anna
    Ferrara, 44124, Italy
  • AOU Careggi
    Firenze, 50134, Italy
  • IRCCS Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Opsedale San Martino di Genova
    Genova, 16132, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
  • L'UOC di Ematologia del Policlinico Tor Vergata
    Rome, 00133, Italy
  • Policlinico Universitario Agostino Gemelli
    Rome, 00168, Italy
  • Azienda Ospedaliero Universitaria Senese, Policlinico S. Maria alle Scotte
    Siena, 53100, Italy
  • Ospedale di Circolo-a Fondazione Macchi
    Varese, 21100, Italy
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 700-721, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of

Showing the first 100 of 131 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kang D, Ludwig E, Jaworowicz D, Huang H, Fiedler-Kelly J, Cortes J, Ganguly S, Khaled S, Kramer A, Levis M, Martinelli G, Perl A, Russell N, Abutarif M, Choi Y, Yin O. Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2021 Apr;87(4):513-523. doi: 10.1007/s00280-020-04204-y. Epub 2021 Jan 8. PubMed 33415416 ↗
  • Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Kramer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum In: Lancet Oncol. 2019 Jul;20(7):e346. doi: 10.1016/S1470-2045(19)30426-7. PubMed 31175001 ↗
  • Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31. PubMed 29859851 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Feb 2018, 45 months.

Results were first posted in Jan 2020, 1 year 11 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 45 months is close to that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2014
First posted
Jan 20, 2014
StartActual
May 2014
Primary completionActual
Feb 22, 2018
CompletionActual
Sep 8, 2020
Results first posted
Jan 27, 2020
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02039726
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
May 2014
Primary completion
Feb 22, 2018
Completion
Sep 8, 2020
Results posted
Jan 27, 2020
Last update
Feb 24, 2021

Study contacts

Jorge E. Cortes, MD
principal investigator · M.D. Anderson Cancer Center
Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion